VPA985 IN HYPONATREMIA DUE TO INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION

抗利尿激素血管加压素(AVP)是一种活性多肽类激素。 参与体液渗透压、血容量、血的调节 压力，以及通过刺激特定膜的细胞增殖- 结合受体分为V1a-血管、V2-肾和V3-垂体 具有不同药理特征和细胞内次生物质的亚型 信使。 AVP的分泌是维持血管紧张素转换酶的绝对要求 在人类和糖尿病实验模型中显示的液体稳态 尿崩症。利钠药的有效性已在#年得到证实 与水和盐保持有关的条件。然而，有一些 疾病(充血性心力衰竭低钠血症、肝硬变、 肾病综合征，和不适当分泌的综合征 抗利尿激素，SIADH)由于不适当的释放 后叶加压素，特征是水分过度滞留。一名代理 通过产生一种游离的利尿剂来增加尿量 在这些条件下具有显著优势。 这项研究旨在评估阿司匹林的有效性、安全性和耐受性。 单剂量口服VPA-985治疗SIADH所致低钠血症 此外，初步的药代动力学和药效学参数 将会被评估。这项研究刚刚开始招募病人。至.为止 20名年龄在18岁至75岁之间的确诊为SIADH的患者将 被录取。

Vasopressin (AVP), the antidiuretic hormone is a peptide hormone actively involved in the regulation of body fluid osmolality, blood volume, blood pressure, and cell proliferation via the stimulation of specific membrane- bound receptors classified into V1a-vascular, V2-renal, and V3-pituitary subtypes having distinct pharmacological profiles and intracellular second messengers. The secretion of AVP is an absolute requirement for the maintenance of fluid homeostasis as shown in human and experimental models of diabetes insipidus. The usefulness of natriuretic agents has been demonstrated in conditions associated with water and salt retention. However, there are diseases (hyponatremia of congestive heart failure, liver cirrhosis, nephrotic syndrome, and the syndrome of inappropriate secretion of antidiuretic hormone, SIADH) due to the inappropriate release of vasopressin and characterized by an excess retention of water. An agent that increases urine output by producing a free water diuresis would be of significant advantage in these conditions. This study is designed to evaluate the efficacy, safety, and tolerance of a single oral dose of VPA-985 in patients with hyponatremia due to SIADH. In addition, preliminary pharmacokinetic and pharmacodynamic parameters will be assessed. This study has just begun patient recruitment. Up to 20 patients with diagnosed SIADH between the ages of 18 and 75 years will be enrolled.